The availability of direct-acting antiviral (DAA) treatments for hepatitis C (HCV) could lead to reductions in HCV-related liver disease as well as HCV transmission. The simplicity of DAA treatments is also revolutionising existing models of HCV care. HCV treatment can now be managed in primary healthcare and community settings rather than just in hospital settings, with novel point-of-care diagnostic tests.
Many countries are now developing elimination strategies, but there is little understanding of what is required to achieve these goals. Myanmar has set national HCV targets to achieve 50 per cent of people diagnosed and 50 per cent treated by 2030.
This project used mathematical modelling to estimate the national treatment scale-up required to reach the HCV elimination targets by 2030 and to determine the expected budget impact and return on investment over time of the optimal screening and treatment strategy.
Gilead Sciences Inc.
National Hepatitis Control Program